"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A study to find out what men think is important when making decisions about treatment for prostate cancer (COMPARe study)
This was a study to learn more about how men made decisions about prostate cancer treatment.
More about this trial
Another option is to not start treatment but be closely monitored instead. This is active surveillance.
This is only suitable for men with a low or intermediate risk of their cancer growing.
All the treatments are different. So are the side effects, and how long these are likely to last. Deciding which treatment to have can be difficult. Researchers wanted to learn more about how men with prostate cancer made choices between the treatment options.
In this study, they asked men what was most important to them when deciding between one treatment and another.
Summary of results
The study team surveyed 650 men with localised prostate cancer. This was within 1 week of their diagnosis and before they chose their treatment.
In the survey they chose their preferred treatment based on 6 features:
- the type of treatment for localised prostate cancer
- how long it took to return to normal activities after treatment
- the amount of men able to maintain an erection a year after treatment
- the amount of men who had no problems controlling passing urine a year after treatment
- the amount of men not needing any more treatment 10 to 15 years after initial treatment
- the amount of men who survive 10 to 15 years after treatment
The team concluded that all men chose quality of life over increasing their chance of surviving.
They also looked at the men with low risk or intermediate risk prostate cancer. These men also had the option of active surveillance. They concluded that they chose active surveillance rather than treatment.
More detailed information
There is more information about this research in the reference below.
Please note, the summary of this article may not be in plain English. It has been written for health care professionals and researchers.
Verity Watson, Neil McCartan, Nicolas Krucien, Victor Abu, Divine Ikenwilo, Mark Emberton and Hashim U. Ahmedk
Journal of Urology, Vol. 204, 273-280, August 2020
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists (
How to join a clinical trial
Dr Verity Watson
Professor Mark Emberton
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
University College London (UCL)